Danaher (NYSE:DHR) PT Raised to $271.00 at Robert W. Baird

Danaher (NYSE:DHR) had its price objective increased by equities research analysts at Robert W. Baird from $259.00 to $271.00 in a note issued to investors on Wednesday, Benzinga reports. The brokerage presently has an “outperform” rating on the conglomerate’s stock. Robert W. Baird’s price objective would suggest a potential upside of 10.24% from the company’s current price.

A number of other brokerages also recently commented on DHR. Royal Bank of Canada boosted their price objective on shares of Danaher from $254.00 to $282.00 and gave the company an “outperform” rating in a research report on Wednesday, January 31st. KeyCorp lifted their target price on shares of Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a research note on Thursday, February 1st. Raymond James lifted their target price on shares of Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a research note on Wednesday, January 31st. Citigroup lifted their target price on shares of Danaher from $255.00 to $280.00 and gave the company a “buy” rating in a research note on Wednesday, January 31st. Finally, Barclays lifted their target price on shares of Danaher from $240.00 to $260.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 10th. Six analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat, Danaher has an average rating of “Moderate Buy” and an average price target of $270.00.

Danaher Stock Performance

Danaher stock opened at $245.82 on Wednesday. The firm’s 50 day simple moving average is $248.94 and its 200-day simple moving average is $230.88. The company has a market cap of $182.04 billion, a P/E ratio of 41.66, a price-to-earnings-growth ratio of 4.24 and a beta of 0.83. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.68 and a quick ratio of 1.37. Danaher has a fifty-two week low of $182.09 and a fifty-two week high of $259.00.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, topping the consensus estimate of $1.72 by $0.20. Danaher had a net margin of 16.78% and a return on equity of 11.48%. The business had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.62 billion. During the same period last year, the firm posted $2.36 earnings per share. The firm’s quarterly revenue was down 2.6% compared to the same quarter last year. As a group, equities research analysts predict that Danaher will post 7.62 EPS for the current year.

Insider Buying and Selling

In related news, SVP Georgeann Couchara sold 2,622 shares of the business’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total transaction of $636,280.74. Following the transaction, the senior vice president now owns 4,244 shares of the company’s stock, valued at $1,029,891.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, SVP Brian W. Ellis sold 4,000 shares of the company’s stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $250.01, for a total value of $1,000,040.00. Following the sale, the senior vice president now owns 29,830 shares of the company’s stock, valued at approximately $7,457,798.30. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Georgeann Couchara sold 2,622 shares of the company’s stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total transaction of $636,280.74. Following the completion of the sale, the senior vice president now directly owns 4,244 shares in the company, valued at approximately $1,029,891.48. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 84,132 shares of company stock valued at $21,022,795. 11.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Danaher

Large investors have recently made changes to their positions in the company. Tsfg LLC lifted its position in Danaher by 733.3% during the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after buying an additional 88 shares in the last quarter. Cape Investment Advisory Inc. acquired a new position in Danaher during the 4th quarter valued at about $25,000. BKM Wealth Management LLC acquired a new position in Danaher during the 4th quarter valued at about $27,000. Redmont Wealth Advisors LLC acquired a new position in Danaher during the 1st quarter valued at about $30,000. Finally, Wetzel Investment Advisors Inc. acquired a new position in Danaher during the 4th quarter valued at about $29,000. Institutional investors own 79.05% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.